Furthermore, this reactivation of p53 cooperated with vemurafenib, a BRAFV600E and BRAFV600K inhibitor, to suppress melanoma growth in vivo, by inducing p53-dependent apoptosis and growth suppression. Here, TP53 is linked to melanoma.